Genprex, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genprex, Inc. on November 4, 2024. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing compliance rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On November 4, 2024, Genprex received confirmation from Nasdaq Staff that it has regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)). This resolves a prior non-compliance notice issued on September 26, 2024, which cited the company's failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of new risks. The document confirms that the Minimum Bid Price Requirement matter is now closed.
Key Facts for Investor Verification
- Genprex has officially regained compliance with Nasdaq's $1.00 minimum bid price requirement.
- The listing deficiency matter initiated in September 2024 is now closed.
- The company's common stock (Symbol: GNPX) remains listed on The Nasdaq Capital Market.
- No financial data or operational updates are included in this specific filing.